Stephen S.Y. Lam

407 total citations
20 papers, 267 citations indexed

About

Stephen S.Y. Lam is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, Stephen S.Y. Lam has authored 20 papers receiving a total of 267 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hematology, 9 papers in Molecular Biology and 5 papers in Genetics. Recurrent topics in Stephen S.Y. Lam's work include Acute Myeloid Leukemia Research (10 papers), Chronic Myeloid Leukemia Treatments (4 papers) and Cancer Genomics and Diagnostics (3 papers). Stephen S.Y. Lam is often cited by papers focused on Acute Myeloid Leukemia Research (10 papers), Chronic Myeloid Leukemia Treatments (4 papers) and Cancer Genomics and Diagnostics (3 papers). Stephen S.Y. Lam collaborates with scholars based in Hong Kong, United States and China. Stephen S.Y. Lam's co-authors include Anskar Y.H. Leung, Anskar Y.H. Leung, Yok‐Lam Kwong, Amina F.A.S. Teunisse, Martijn J. W. E. Rabelink, A.G. Jochemsen, Harinder Gill, Bai‐Liang He, Kirsten Lodder and Mieke Schutte and has published in prestigious journals such as Blood, American Journal of Respiratory and Critical Care Medicine and Cancer.

In The Last Decade

Stephen S.Y. Lam

17 papers receiving 265 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stephen S.Y. Lam Hong Kong 9 172 116 61 46 37 20 267
Jeffrey Strovel United States 11 264 1.5× 97 0.8× 61 1.0× 28 0.6× 22 0.6× 24 340
Véronique Mansat‐De Mas France 7 308 1.8× 129 1.1× 107 1.8× 35 0.8× 39 1.1× 7 391
Héléna Boutzen France 8 234 1.4× 165 1.4× 61 1.0× 39 0.8× 29 0.8× 11 329
Miriam Kull Germany 8 279 1.6× 130 1.1× 61 1.0× 17 0.4× 23 0.6× 16 335
Anuradha Illendula United States 10 317 1.8× 191 1.6× 87 1.4× 44 1.0× 35 0.9× 19 435
Liting Xue United States 8 224 1.3× 171 1.5× 46 0.8× 39 0.8× 76 2.1× 20 368
Jiro Minami Japan 9 144 0.8× 103 0.9× 68 1.1× 28 0.6× 30 0.8× 21 266
Fiorella Schischlik Austria 9 215 1.3× 70 0.6× 68 1.1× 37 0.8× 78 2.1× 19 314
Elena Ceccacci Italy 7 301 1.8× 68 0.6× 58 1.0× 33 0.7× 16 0.4× 9 347

Countries citing papers authored by Stephen S.Y. Lam

Since Specialization
Citations

This map shows the geographic impact of Stephen S.Y. Lam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen S.Y. Lam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen S.Y. Lam more than expected).

Fields of papers citing papers by Stephen S.Y. Lam

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen S.Y. Lam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen S.Y. Lam. The network helps show where Stephen S.Y. Lam may publish in the future.

Co-authorship network of co-authors of Stephen S.Y. Lam

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen S.Y. Lam. A scholar is included among the top collaborators of Stephen S.Y. Lam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen S.Y. Lam. Stephen S.Y. Lam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Henderson, Louise M., Roger Y. Kim, Nichole T. Tanner, et al.. (2025). Lung Cancer Screening and Incidental Findings: A Research Agenda: An Official American Thoracic Society Research Statement. American Journal of Respiratory and Critical Care Medicine. 211(3). 436–451. 3 indexed citations
2.
3.
Lam, Stephen S.Y., et al.. (2023). Distinct karyotypic and mutational landscape in trisomy AML. British Journal of Haematology. 204(3). 939–944. 2 indexed citations
4.
Man, Cheuk Him, Xiaoyuan Zeng, Wing Lam, et al.. (2022). Regulation of proton partitioning in kinase-activating acute myeloid leukemia and its therapeutic implication. Leukemia. 36(8). 1990–2001. 3 indexed citations
5.
Lam, Stephen S.Y., et al.. (2021). First Confirmed Case of IgE-Mediated Hypersensitivity to Evolucumab with Cross-Reactivity to Alirocumab. The Journal of Allergy and Clinical Immunology In Practice. 9(9). 3481–3482.e1.
6.
Lam, Stephen S.Y. & Anskar Y.H. Leung. (2020). Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML. International Journal of Molecular Sciences. 21(4). 1537–1537. 40 indexed citations
7.
He, Bai‐Liang, Ning Yang, Cheuk Him Man, et al.. (2020). Follistatin is a novel therapeutic target and biomarker in FLT 3/ ITD acute myeloid leukemia. EMBO Molecular Medicine. 12(4). e10895–e10895. 14 indexed citations
8.
Zhang, Chunxiao, Stephen S.Y. Lam, Garret M. K. Leung, et al.. (2019). Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms‐like tyrosine kinase 3. Cancer. 126(2). 344–353. 22 indexed citations
9.
Marshall, Erin A., et al.. (2017). P1.02-052 Signal Regulatory Protein a (SIRPA): A Key Regulator of the EGFR Pathway Demonstrates Both Tumor Suppressive and Oncogenic Properties. Journal of Thoracic Oncology. 12(1). S519–S519. 1 indexed citations
10.
Jassem, Jacek, Filippo de Marinis, David R. Spigel, et al.. (2017). IMpower110: Phase III trial of 1L atezolizumab in PD-L1–selected chemotherapy-naive NSCLC. Annals of Oncology. 28. ii50–ii50. 3 indexed citations
11.
Lam, Stephen S.Y., Bai‐Liang He, & Anskar Y.H. Leung. (2017). Treatment of acute myeloid leukemia in the next decade – Towards real-time functional testing and personalized medicine. Blood Reviews. 31(6). 418–425. 10 indexed citations
12.
Marinis, Filippo de, Jacek Jassem, David R. Spigel, et al.. (2016). 480TiP IMpower110: Phase III study on 1L atezolizumab (atezo) in PD-L1–selected chemotherapy (chemo)-naive NSCLC patients (pts). Annals of Oncology. 27. ix154–ix154. 4 indexed citations
13.
Lam, Stephen S.Y., Bai‐Liang He, Harinder Gill, et al.. (2016). Homoharringtonine (omacetaxine mepesuccinate) as an adjunct forFLT3-ITD acute myeloid leukemia. Science Translational Medicine. 8(359). 359ra129–359ra129. 51 indexed citations
14.
Gou, Xue, et al.. (2015). Cell adhesion manipulation through single cell assembly for characterization of initial cell-to-cell interaction. BioMedical Engineering OnLine. 14(1). 114–114. 12 indexed citations
15.
Man, Cheuk Him, et al.. (2014). Targeting Polo-like Kinase in Acute Myeloid Leukemia. Blood. 124(21). 2234–2234. 1 indexed citations
16.
Man, Cheuk Him, Stephen S.Y. Lam, Howard C.H. Chow, et al.. (2014). A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD+ AML. Blood. 123(16). 2530–2539. 34 indexed citations
17.
Lam, Stephen S.Y., Kirsten Lodder, Amina F.A.S. Teunisse, et al.. (2010). Role of Mdm4 in drug sensitivity of breast cancer cells. Oncogene. 29(16). 2415–2426. 42 indexed citations
18.
Campbell, Jennifer, William W. Lockwood, Timon P.H. Buys, et al.. (2008). Integrative genomic and gene expression analysis of chromosome 7 identified novel oncogene loci in non-small cell lung cancer. Genome. 51(12). 1032–1039. 24 indexed citations
19.
Buys, Timon P.H., Yuzhuo Wang, John Yee, et al.. (2005). E13. Identification of genomic changes associated with resistanceto standard chemotherapy in a xenograft model of human NSCLC. Lung Cancer. 49. S21–S21.
20.
Garnis, Cathie, Bradley P. Coe, Adrian Ishkanian, et al.. (2004). Construction and Optimization of Chromosome Arm-Specific Comparative Genomic Hybridization Arrays for Identifying Genetic Alterations in Preinvasive Lung Cancers. CHEST Journal. 125(5). 104S–105S. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jeffrey Strovel Breakdown of academic impact, for papers by Véronique Mansat‐De Mas Breakdown of academic impact, for papers by Héléna Boutzen Breakdown of academic impact, for papers by Miriam Kull Breakdown of academic impact, for papers by Anuradha Illendula Breakdown of academic impact, for papers by Liting Xue Breakdown of academic impact, for papers by Jiro Minami Breakdown of academic impact, for papers by Fiorella Schischlik Breakdown of academic impact, for papers by Elena Ceccacci
Rankless by CCL
2026